MBX Biosciences, Inc. MBX Other Commercial Liabilities
Other Commercial Liabilities at other companies
Other financials
Where this comes from
Reported directly by MBX Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about MBX Biosciences, Inc.'s other commercial liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MBX Biosciences, Inc.'s other commercial liabilities?
- MBX Biosciences, Inc. (MBX) reported other commercial liabilities of $7.42M in Q1 2026.
- How has MBX Biosciences, Inc.'s other commercial liabilities changed year-over-year?
- MBX Biosciences, Inc.'s other commercial liabilities increased by 21.4% year-over-year, from $6.11M to $7.42M.
- What is the long-term trend for MBX Biosciences, Inc.'s other commercial liabilities?
- Over 2 years (2023 to 2025), MBX Biosciences, Inc.'s other commercial liabilities has grown at a 127.7% compound annual growth rate (CAGR), from $2.38M to $12.35M.